{"id":9004111222136573,"date":"2024-02-22T16:44:10","date_gmt":"2024-02-22T16:44:10","guid":{"rendered":"https:\/\/www.hgf.com\/?p=9004111222136573"},"modified":"2025-11-13T20:09:01","modified_gmt":"2025-11-13T20:09:01","slug":"quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car","status":"publish","type":"post","link":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/","title":{"rendered":"Quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR ?"},"content":{"rendered":"<p class=\"p__large\">La premi\u00e8re g\u00e9n\u00e9ration de cellules CAR-T a \u00e9t\u00e9 d\u00e9couverte en 1993 lorsque la r\u00e9gion variable d&#8217;un anticorps a \u00e9t\u00e9 fusionn\u00e9e aux r\u00e9gions constantes d&#8217;un r\u00e9cepteur de cellules T. Aujourd&#8217;hui, 20 ans plus tard, le march\u00e9 mondial de la th\u00e9rapie cellulaire CAR-T vaut environ 8,44 milliards de dollars et devrait atteindre environ 88,5 milliards de dollars d&#8217;ici 2032. <\/p>\n<p>Les progr\u00e8s scientifiques dans le domaine de l&#8217;immunoth\u00e9rapie du cancer ont conduit aux six approbations suivantes de la th\u00e9rapie cellulaire CAR-T par la FDA et l&#8217;EMA, ainsi que par d&#8217;autres agences de r\u00e9glementation.<\/p>\n<p><img decoding=\"async\" class=\"alignnone wp-image-9004111222129781\" src=\"https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/Graph-3-300x214.jpg\" alt=\"\" width=\"700\" height=\"499\" srcset=\"https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/Graph-3-300x214.jpg 300w, https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/Graph-3-1024x730.jpg 1024w, https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/Graph-3-768x548.jpg 768w, https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/Graph-3-1536x1095.jpg 1536w, https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/Graph-3-2048x1460.jpg 2048w, https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/Graph-3-1920x1369.jpg 1920w\" sizes=\"(max-width: 700px) 100vw, 700px\" \/><\/p>\n<p>Compte tenu du succ\u00e8s de ces traitements \u00e0 base de cellules CAR-T, quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR-T et que fait-on pour rendre ces traitements plus facilement disponibles ?<\/p>\n<h5><strong><em>Cellules tueuses naturelles CAR<\/em><\/strong><\/h5>\n<p>La toxicit\u00e9 la plus importante des cellules CAR-T est connue sous le nom de syndrome de lib\u00e9ration de cytokines (SLC). Le SLC est caus\u00e9 par une lib\u00e9ration abondante de cytokines pro-inflammatoires provenant des cellules cibles et des cellules effectrices immunitaires. L&#8217;une des approches adopt\u00e9es pour r\u00e9soudre ce probl\u00e8me est la th\u00e9rapie cellulaire CAR-NK. Contrairement aux cellules CAR-T qui peuvent lib\u00e9rer des cytokines pro-inflammatoires, les cellules NK ont un spectre diff\u00e9rent de cytokines s\u00e9cr\u00e9t\u00e9es, qui sont consid\u00e9r\u00e9es comme plus s\u00fbres que celles induites par les cellules CAR-T. Il existe actuellement 39 essais cliniques publi\u00e9s recrutant des patients pour la th\u00e9rapie cellulaire CAR-NK.    <\/p>\n<h5><strong><em>Cellules CAR-T allog\u00e9niques<\/em><\/strong><\/h5>\n<p>Comme le refl\u00e8te leur prix, une autre limite de la th\u00e9rapie cellulaire CAR-T est le co\u00fbt et le temps n\u00e9cessaires \u00e0 la fabrication de ces produits. Les cellules CAR-T actuellement approuv\u00e9es par la FDA sont g\u00e9n\u00e9r\u00e9es \u00e0 partir de cellules de patients, connues sous le nom de cellules T autologues. Non seulement ce processus de g\u00e9n\u00e9ration de cellules CAR-T est long et co\u00fbteux, mais souvent les cellules T du patient sont \u00e9puis\u00e9es car elles ont d\u00e9j\u00e0 re\u00e7u une chimioth\u00e9rapie et\/ou une radioth\u00e9rapie. En revanche, l&#8217;utilisation de cellules T obtenues aupr\u00e8s de donneurs sains (cellules T allog\u00e9niques) fournit des quantit\u00e9s \u00e9lev\u00e9es et fonctionnelles de cellules, permettant des produits de cellules CAR-T \u00ab pr\u00eats \u00e0 l&#8217;emploi \u00bb. Il existe actuellement 33 essais cliniques publi\u00e9s recrutant des patients pour la th\u00e9rapie cellulaire CAR-T allog\u00e9nique.    <\/p>\n<h5><strong><em>Cellules CAR contr\u00f4lables<\/em><\/strong><\/h5>\n<p>Un autre probl\u00e8me rencontr\u00e9 par les th\u00e9rapies cellulaires CAR-T actuelles est l&#8217;\u00e9puisement des cellules T. L&#8217;\u00e9puisement des cellules T est caus\u00e9 par une signalisation excessive de l&#8217;antig\u00e8ne, entra\u00eenant une r\u00e9ponse immunitaire excessive prolong\u00e9e qui laisse les cellules CAR-T \u00e9puis\u00e9es avant qu&#8217;elles ne puissent \u00e9liminer les tumeurs. En tant que tel, limiter ou interrompre l&#8217;interaction CAR&nbsp;:antig\u00e8ne est une strat\u00e9gie int\u00e9ressante pour am\u00e9liorer l&#8217;\u00e9puisement des cellules CAR-T. Pour contrer l&#8217;\u00e9puisement des cellules CAR-T, des CAR \u00e0 m\u00e9diation par adaptateur ont \u00e9t\u00e9 d\u00e9velopp\u00e9s. Avec les syst\u00e8mes CAR \u00e0 m\u00e9diation par adaptateur, la cellule CAR-T ne se lie pas directement \u00e0 l&#8217;antig\u00e8ne tumoral. Au lieu de cela, la cellule CAR-T se lie \u00e0 un adaptateur et l&#8217;adaptateur se lie \u00e0 l&#8217;antig\u00e8ne tumoral. Les mol\u00e9cules d&#8217;adaptateur sont ensuite administr\u00e9es aux patients et agissent comme un lien entre la tumeur et la cellule CAR-T, activant efficacement la cellule CAR-T. En contr\u00f4lant efficacement la fonction des cellules CAR-T, l&#8217;activit\u00e9 des cellules CAR-T peut \u00eatre r\u00e9gul\u00e9e m\u00eame une fois administr\u00e9e \u00e0 un patient, ce qui permet un traitement plus s\u00fbr et plus efficace.       <\/p>\n<h5><strong><em>Au-del\u00e0 du cancer<\/em><\/strong><\/h5>\n<p>\u00c0 l&#8217;heure actuelle, la th\u00e9rapie cellulaire CAR-T n&#8217;a \u00e9t\u00e9 approuv\u00e9e que pour une utilisation dans certains cancers. Aliment\u00e9 par le taux de r\u00e9mission sans pr\u00e9c\u00e9dent de 90&nbsp;% d\u00e9montr\u00e9 par la plupart des th\u00e9rapies cellulaires CAR-T approuv\u00e9es, il existe plus de 600 essais cliniques CAR-T en cours ax\u00e9s sur une gamme de traitements contre le cancer. Cependant, la th\u00e9rapie cellulaire CAR ne se limite pas au traitement du cancer. Des \u00e9tudes cliniques r\u00e9centes utilisant des cellules CAR-T pour traiter le VIH ont d\u00e9montr\u00e9 des r\u00e9sultats s\u00fbrs et positifs. La th\u00e9rapie cellulaire CAR a \u00e9galement montr\u00e9 des r\u00e9sultats remarquables dans les maladies fibrotiques telles que la fibrose cardiaque.    <\/p>\n<p>En conclusion, la th\u00e9rapie cellulaire CAR continue de faire des progr\u00e8s significatifs, et bien qu&#8217;il reste encore plusieurs d\u00e9fis \u00e0 surmonter, l&#8217;avenir de la th\u00e9rapie cellulaire CAR rec\u00e8le un potentiel passionnant.<\/p>\n<hr>\n<h5 class=\"p__medium\">Cet article a \u00e9t\u00e9 pr\u00e9par\u00e9 par la mandataire en brevets europ\u00e9ens <a href=\"https:\/\/www.hgf.com\/fr\/our-people\/alexandra-wood\/\">Alexandra Wood<\/a>.<\/h5>\n","protected":false},"excerpt":{"rendered":"<p>La premi\u00e8re g\u00e9n\u00e9ration de cellules CAR-T a \u00e9t\u00e9 d\u00e9couverte en 1993 lorsque la r\u00e9gion variable d&#8217;un anticorps a \u00e9t\u00e9 fusionn\u00e9e aux r\u00e9gions constantes d&#8217;un r\u00e9cepteur de cellules T. Aujourd&#8217;hui, 20 &hellip;<\/p>\n","protected":false},"author":473,"featured_media":9004111222136579,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[536,517],"tags":[],"class_list":["post-9004111222136573","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-centre-de-connaissances","sector_groups-sciences-de-la-vie"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR ? - HGF<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR ?\" \/>\n<meta property=\"og:description\" content=\"La premi\u00e8re g\u00e9n\u00e9ration de cellules CAR-T a \u00e9t\u00e9 d\u00e9couverte en 1993 lorsque la r\u00e9gion variable d&#039;un anticorps a \u00e9t\u00e9 fusionn\u00e9e aux r\u00e9gions constantes d&#039;un\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/\" \/>\n<meta property=\"og:site_name\" content=\"HGF\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-22T16:44:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-13T20:09:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Katie Pilgrim\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hgf_ip\" \/>\n<meta name=\"twitter:site\" content=\"@hgf_ip\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Katie Pilgrim\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/\"},\"author\":{\"name\":\"Katie Pilgrim\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/#\\\/schema\\\/person\\\/c7c1ab6d978273ea223510a2f207dd04\"},\"headline\":\"Quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR ?\",\"datePublished\":\"2024-02-22T16:44:10+00:00\",\"dateModified\":\"2025-11-13T20:09:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/\"},\"wordCount\":816,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg\",\"articleSection\":[\"Articles\",\"Centre de connaissances\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/\",\"name\":\"Quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR ? - HGF\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg\",\"datePublished\":\"2024-02-22T16:44:10+00:00\",\"dateModified\":\"2025-11-13T20:09:01+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/centre-de-connaissances\\\/articles\\\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/\",\"name\":\"HGF\",\"description\":\"Intellectual Property Rights specialists\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/#organization\",\"name\":\"HGF\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"width\":696,\"height\":696,\"caption\":\"HGF\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hgf_ip\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hgf-limited-intellectual-property-specialists\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/fr\\\/#\\\/schema\\\/person\\\/c7c1ab6d978273ea223510a2f207dd04\",\"name\":\"Katie Pilgrim\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e3b963facae8a3c7ba467afd3c9fd6b67ad50e4022d0eadc099f4ce6cb860808?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e3b963facae8a3c7ba467afd3c9fd6b67ad50e4022d0eadc099f4ce6cb860808?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e3b963facae8a3c7ba467afd3c9fd6b67ad50e4022d0eadc099f4ce6cb860808?s=96&d=mm&r=g\",\"caption\":\"Katie Pilgrim\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR ? - HGF","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/","og_locale":"fr_FR","og_type":"article","og_title":"Quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR ?","og_description":"La premi\u00e8re g\u00e9n\u00e9ration de cellules CAR-T a \u00e9t\u00e9 d\u00e9couverte en 1993 lorsque la r\u00e9gion variable d'un anticorps a \u00e9t\u00e9 fusionn\u00e9e aux r\u00e9gions constantes d'un","og_url":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/","og_site_name":"HGF","article_published_time":"2024-02-22T16:44:10+00:00","article_modified_time":"2025-11-13T20:09:01+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg","type":"image\/jpeg"}],"author":"Katie Pilgrim","twitter_card":"summary_large_image","twitter_creator":"@hgf_ip","twitter_site":"@hgf_ip","twitter_misc":{"\u00c9crit par":"Katie Pilgrim","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/#article","isPartOf":{"@id":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/"},"author":{"name":"Katie Pilgrim","@id":"https:\/\/www.hgf.com\/fr\/#\/schema\/person\/c7c1ab6d978273ea223510a2f207dd04"},"headline":"Quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR ?","datePublished":"2024-02-22T16:44:10+00:00","dateModified":"2025-11-13T20:09:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/"},"wordCount":816,"publisher":{"@id":"https:\/\/www.hgf.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg","articleSection":["Articles","Centre de connaissances"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/","url":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/","name":"Quelles sont les prochaines \u00e9tapes pour la th\u00e9rapie cellulaire CAR ? - HGF","isPartOf":{"@id":"https:\/\/www.hgf.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/#primaryimage"},"image":{"@id":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg","datePublished":"2024-02-22T16:44:10+00:00","dateModified":"2025-11-13T20:09:01+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.hgf.com\/fr\/centre-de-connaissances\/articles\/quelles-sont-les-prochaines-etapes-pour-la-therapie-cellulaire-car\/#primaryimage","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2024\/02\/65d87ad504240-national-cancer-institute-oCLuFi9GYNA-unsplash.jpg","width":2560,"height":1707},{"@type":"WebSite","@id":"https:\/\/www.hgf.com\/fr\/#website","url":"https:\/\/www.hgf.com\/fr\/","name":"HGF","description":"Intellectual Property Rights specialists","publisher":{"@id":"https:\/\/www.hgf.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hgf.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.hgf.com\/fr\/#organization","name":"HGF","url":"https:\/\/www.hgf.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.hgf.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","width":696,"height":696,"caption":"HGF"},"image":{"@id":"https:\/\/www.hgf.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hgf_ip","https:\/\/www.linkedin.com\/company\/hgf-limited-intellectual-property-specialists\/"]},{"@type":"Person","@id":"https:\/\/www.hgf.com\/fr\/#\/schema\/person\/c7c1ab6d978273ea223510a2f207dd04","name":"Katie Pilgrim","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/e3b963facae8a3c7ba467afd3c9fd6b67ad50e4022d0eadc099f4ce6cb860808?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e3b963facae8a3c7ba467afd3c9fd6b67ad50e4022d0eadc099f4ce6cb860808?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3b963facae8a3c7ba467afd3c9fd6b67ad50e4022d0eadc099f4ce6cb860808?s=96&d=mm&r=g","caption":"Katie Pilgrim"}}]}},"_links":{"self":[{"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/posts\/9004111222136573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/users\/473"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/comments?post=9004111222136573"}],"version-history":[{"count":0,"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/posts\/9004111222136573\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/media\/9004111222136579"}],"wp:attachment":[{"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/media?parent=9004111222136573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/categories?post=9004111222136573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hgf.com\/fr\/wp-json\/wp\/v2\/tags?post=9004111222136573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}